| Objective: To observe the prevention and treatment effect of modified angelica Buxue Decoction on the toxic and side effects of chemotherapy with XELOX regimen in colorectal cancer.Methods: A total of 51 patients admitted to 940 Hospital of the Chinese People’s Liberation Army Joint Logistic Support Force from December 2021 to January 2023 with postoperative pathological diagnosis of colon cancer or/and rectal cancer,who were determined to need adjuvant chemotherapy according to the CSCO guidelines and classified as spleen&kidney deficiency based on TCM syndrome differentiation were randomly divided into the experimental group and the control group.The experimental group received XELOX regimen combined with Chinese herbal medicine angelica Buxue Decoction,while the control group only received XELOX regimen.Both groups received liver protection,antiemesis and whitening treatment.After 4 consecutive cycles of observation,the changes of WBC,NEU,HGB,PLT count,KPS score,TCM syndrome score,ALT,AST,Cr count before and after treatment were compared between the two groups,and adverse reactions were recorded.Results:1.Myelosuppression indexes: There were no significant differences in WBC,NEU,HGB and PLT between the two groups before treatment(P > 0.05).The WBC count of experimental group and control group was 4.74±1.76 vs 3.61±0.72,P=0.006 on day 3,3.91±1.04 vs3.00±0.70,P=0.000,and 4.28±1.20 vs 3.65±0.87 on day 14,respectively.P=0.022)were decreased,with statistical difference(P < 0.05),the decreasing trend of experimental group was slower than that of control group,and the WBC count recovered to the pre-treatment level on the 14 th day after treatment.There was no difference in NEU count between the experimental group and the control group at day 3(2.31±0.86 vs 2.46±1.11,P=0.41),and at day 7(1.67±0.45 vs 2.21±0.86,P=0.41)and the 14 th day(2.09±0.54 vs 2.63±0.59,P=0.002).There was no significant difference between the experimental group and the control group at1 day before treatment and 14 days after treatment [(2.46±0.79 vs 2.09±0.54,P=0.002,P=0.458),(2.46±0.99 vs 2.63±0.59,P=0.531)].There was no statistical difference in HGB count between the two groups during treatment(P > 0.05),and there was no statistical difference between the test group 1 day before treatment and 14 days after treatment(127.16±18.88 vs 108.36±19.53,P=0.458).There was a statistical difference between the control group 1 day before treatment and 14 days after treatment(121.78±17.69 vs117.13±15.85,P=0.001).There was no significant difference in PLT count between the two groups on day 3(165.78±49.61 vs 140.68±46.83,P=0.084)and day 7(142.13±40.99 vs121.48±41.37,P=0.096)(P > 0.05).There was a difference between the two groups at the14 th day of treatment(129.57±35.67 vs 104.64±33.81,P=0.019).The experimental group and the control group were statistically different 1 day before treatment and 14 days after treatment by intra-group comparison [(179.17±47.62 vs 129.57±35.67,P=0.019),(166.12±60.42 vs 104.64±33.81,P=0.000)].The grade of myelosuppression in the experimental group was mostly grade Ⅰ,and that in the control group was mostly grade Ⅱ.2.KPS score: There was no significant difference between the experimental group and the control group before treatment(81.74±6.36 vs 81.20±5.88,P=0.766).After treatment,KPS scores of the experimental group and the control group were significantly different(80.87±5.83 vs 72.00±8.00,P=0.000),and KPS scores of the experimental group were improved,stable or ineffective in 5,10 and 8 cases,respectively.In the control group,there were 1,5 and 19 patients with improved,stable and ineffective KPS score after treatment,respectively.The effective rate of the two groups was 65.2% vs 24%,with statistical difference(P < 0.05).3.TCM syndrome score: there was no significant difference between the two groups before treatment(11.65±3.58 vs 11.32±3.33,P=0.746).There was no statistical difference in TCM syndrome scores between the experimental group and the control group after treatment(7.78±3.16 vs 9.20±4.55,P=0.232),and there were 5,12 and 6 patients in the experimental group who were effective,stable and ineffective,respectively.In the control group,there were 2 cases of effective,stable and ineffective TCM syndrome scores after treatment,11 cases and 12 cases,respectively.The effective rate of the two groups was 73.9% vs 52%,with no statistical difference(P > 0.05).Conclusion: The added flavor of angelica Buxue decoction can effectively relieve the bone marrow suppression and gastrointestinal reactions of colorectal cancer patients after chemotherapy,and the treatment effect of WBC and NEU is more significant,and can further improve patients’ KPS score,improve patients’ TCM syndromes,improve patients’ quality of life,and make patients have better treatment compliance and completion rate. |
PDF Full Text Request